Aurinia Pharmaceuticals (NASDAQ:AUPH) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) announced its earnings results on Friday. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.01, FiscalAI reports. The business had revenue of $83.70 million during the quarter, compared to analysts’ expectations of $83.61 million. Aurinia Pharmaceuticals had a net margin of 100.84% and a return on equity of 26.11%.

Aurinia Pharmaceuticals Stock Down 3.3%

NASDAQ AUPH opened at $16.65 on Friday. The stock has a fifty day moving average of $16.49 and a 200-day moving average of $15.64. The stock has a market capitalization of $2.22 billion, a P/E ratio of 7.27 and a beta of 1.60. Aurinia Pharmaceuticals has a 52 week low of $12.07 and a 52 week high of $19.25. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.97 and a current ratio of 5.42.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Weiss Ratings upgraded shares of Aurinia Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 22nd. Royal Bank Of Canada raised their price objective on shares of Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the stock a “sector perform” rating in a report on Friday, August 7th. Wall Street Zen cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Bloom Burton raised Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 20th. Finally, Zacks Research lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Aurinia Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $17.75.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s principal product is Lupkynis (voclosporin), an oral calcineurin inhibitor used in combination with other immunosuppressive therapies to treat adults with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus.

Voclosporin was approved by the U.S. Food and Drug Administration in 2021, making Lupkynis the first oral therapy specifically approved in the United States for adult patients with active lupus nephritis.